Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

TOP - November 2017, Vol 10, No 4

Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 - Lung Cancer

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.

Read More
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 - Gynecologic Cancers
Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a PARP inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to findings from 2 clinical trials presented at the 2017 ASCO annual meeting.
Read More
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 - Breast Cancer
OlympiAD provides proof of principle that breast cancers with defects in a specific DNA damage repair pathway are sensitive to a targeted therapy designed to exploit that defect, said Dr Robson.
Read More
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
David King
TOP - November 2017, Vol 10, No 4 - Prostate Cancer

Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.

Read More
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 - Immunotherapy
Chicago, IL—The tumor types amenable to immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) keep expanding and now include sarcoma, which has been difficult to treat.
Read More
From The Editors - TOP November 2017
TOP - November 2017, Vol 10, No 4 - From the Editors

Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.

Read More
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 - Breast Cancer
CDK4/CDK6 inhibitors will most likely not have a role as monotherapy, said Ingrid Mayer, MD, Associate Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, who discussed the study results.
Read More
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
TOP - November 2017, Vol 10, No 4 - Drug Updates
Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults.
Read More
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
TOP - November 2017, Vol 10, No 4 - Multiple Myeloma
According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab.
Read More
Noteworthy Numbers: Peripheral Neuropathy
TOP - November 2017, Vol 10, No 4 - Noteworthy Numbers
Peripheral neuropathy is the result of damage to the peripheral nervous system, the complex network of nerves that transmits messages between the brain and other parts of the body. Such damage can cause impaired movement, loss of sensation in the arms and legs, numbness, tingling, and pain.
Read More
  • 1
  • 2
Page 1 of 2
Results 1 - 10 of 13